Clinical and Genomic Factors Predicting the Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.

Prognosis-related factors for advanced NSCLC with immune checkpoint inhibitors (ICIs) in combination with platinum-doublet chemotherapy have not been determined yet. A recent study by Alessi et al. 1 Alessi J.V. Elkrief A. Ricciuti B. et al. Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC. J Thorac Oncol. 2023; 18: 731-743 Abstract Full Text Full Text PDF Scopus (1) Google Scholar retrospectively used multicenter cohorts with clinicopathologic and genomic data to identify these key factors. The study found that better patient performance, low derived neutrophil-to-lymphocyte ratio, increasing programmed cell death ligand 1 expression, a very high tumor mutation burden (TMB), and STK11/KEAP1/SMARCA4 wild-type status are associated with more clinical benefits from chemoimmunotherapy. 1 Alessi J.V. Elkrief A. Ricciuti B. et al. Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC. J Thorac Oncol. 2023; 18: 731-743 Abstract Full Text Full Text PDF Scopus (1) Google Scholar The study incorporates abundant data; however, several concerns may be discussed before its actual use. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLCJournal of Thoracic OncologyVol. 18Issue 6PreviewAlthough programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay of first-line treatment for advanced NSCLC, factors associated with efficacy of chemoimmunotherapy (CIT) are not well characterized. Full-Text PDF Letter to the Editor: Reply to Zhao, Wu, and MaJournal of Thoracic OncologyVol. 18Issue 6PreviewWe thank Drs. Zhao, Wu, and Ma for their interest in our recent original article entitled “Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer (NSCLC),” in which we identified that better patient performance status (PS), low derived neutrophil-to-lymphocyte ratio in the blood, increasing programmed death-ligand 1 expression, a very high tumor mutational burden (TMB), and STK11/KEAP1/SMARCA4 wild-type status are associated with improved clinical outcomes to first-line chemoimmunotherapy (CIT) in NSCLC. Full-Text PDF